Medicinal signaling cells niche in stromal vascular fraction from lipoaspirate and microfragmented counterpart

Aim To expand our previous findings by increasing the number of patients in a study characterizing medicinal signaling cells (MSC) of stromal vascular fraction from lipoaspirate (SVF-LA) and from microfragmented lipoaspirate (SVF-MLA) applied for the treatment of osteoarthritis (OA). Methods Twenty OA patients, including 8 new patients, acquiring autologous microfragmented adipose tissue were enrolled. In-parallel immunophenotyping of SVF-LA and SVF-MLA was performed. The samples were incubated in a DuraClone SC prototype tube targeting the CD31, CD34, CD45, CD73, CD90, CD105, and CD146 surface markers, stained with the DRAQ7 cell nuclear dye and Live/Dead Yellow Fixable Stain, and analyzed by flow cytometry. Results The population phenotypes in SVF-LA and SVF-MLA samples included [CD31.sup.+][CD34.sup.+][CD73.sup.[+ or -]][CD90.sup.[+ or -]] [CD105.sup.[+ or -]][CD146.sup.[+ or -]] endothelial progenitors (EP), [CD31.sup.+][CD34.sup.-][CD73.sup.[+ or -]][CD90.sup.[+ or -]][CD105.sup.-][CD146.sup.[+ or -]] mature endothelial cells, [CD31.sup.-][CD34.sup.-][CD73.sub.[+ or -]][CD90.sup.+][CD105.sup.-][CD146.sup.+] pericytes, CD3V [CD34.sup.+][CD73.sup.[+ or -]][CD90.sup.+][CD105.sup.-][CD146.sup.+] transitional pericytes, and [CD31.sup.-][CD34.sup.+][CD73.sup.high][CD90.sup.+][CD105.sup.-][CD146.sup.-] supra-adventitial-adipose stromal cells. Compared with the autologous SVF-LA samples, the prevailing cell type in SVF-MLA were EP, which outnumbered leukocytes and supra-adventitial-adipose stromal cells (SA-ASC). The ratio of progenitor cells in SVF-MLA samples differed between female and male patients, showing a higher EP-pericyte and pericyte-SA-ASC ratio in men. Conclusion Our results, hallmarked by EP-enriched anti-inflammatory features and indicating a possible sex-specific impact, contribute to defining the cellular composition of the clinically applied MSC serving as a regenerative cell therapy in OA.